The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Japanese cohort study of first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC) containing fluorouracil, oxaliplatin, and bevacizumab: EMERaLD study, first report.
Keisei Taku
No relevant relationships to disclose
Kou Ohata
No relevant relationships to disclose
Toraji Amano
No relevant relationships to disclose
Yasuo Ohashi
No relevant relationships to disclose
Kentaro Yamazaki
No relevant relationships to disclose
Masaya Watanabe
No relevant relationships to disclose
Shinsuke Satou
No relevant relationships to disclose
Takeshi Ooshima
No relevant relationships to disclose
Go Nishikawa
No relevant relationships to disclose
Hidekazu Hirano
No relevant relationships to disclose